Clinical Trial: A Study of a Novel Precision Medicine Approach for Obesity

U.S., Feb. 8 -- ClinicalTrials.gov registry received information related to the study (NCT06814938) titled 'A Study of a Novel Precision Medicine Approach for Obesity' on Feb. 03.

Brief Summary: This study is being done to assess the efficacy of a saliva- based biomarker to predict response to semaglutide for the treatment of obesity.

Study Start Date: Feb. 15

Study Type: INTERVENTIONAL

Condition: Obesity

Intervention: DRUG: Semaglutide

2.4 mg subcutaneous weekly

DRUG: Placebo

Looks exactly like the study drug, but it contains no active ingredient administered subcutaneous weekly

Recruitment Status: RECRUITING

Sponsor: Mayo Clinic

Information provided by (Responsible Party): Andres J. Acosta, M.D., Ph.D., Mayo Clinic

Disclaime...